Biotech Blog Archives: March 2007
next page ·
28 March 2007
Patent licensees gain more power
I touched briefly on the Medimmune v. Genentech case in a previous Carnival of Biotechnology, but I didn’t go into great detail on the case because I didn’t want to scoop David Morrill who interviewed me for an article on the case.
You can read my thoughts in David’s article, but I’ll go ahead and repeat [...]
continue reading... » 0 Comments
27 March 2007
Carnival of Biotechnology
The latest Carnival of Biotechnology is up at Baby Biotechs. Great job, Brian!
For more information, see the Carnival of Biotechnology Homepage, or submit a link for the next edition. Interested in hosting a future Carnival of Biotechnology? Let me know.
continue reading... » 0 Comments
27 March 2007
Xenotourism: Scary Stuff
Just came across an article on diabetics going to Mexico to receive pig xenotransplants. Unlike other forms of medical tourism, where patients travel to other countries for lower cost treatments, better quality treatments, or to receive ethically questionable organ transplants, xenotransplantation carries significant safety concerns.
Xenotransplantation is the transplantation of organs or tissues from non-humans [...]
continue reading... » One Comment
27 March 2007
The commercial prospects of biogenerics - how much will they save?
This follow-up to my post on the technical reasons why biogenerics are so hard to regulate provides some updates the status of biogenerics, background on the key issues, and the impacts on the industry of the various possible approval schemes.
Clinical Trials
The clinical trial requirement for biogenerics is the leading issue from a regulatory and cost [...]
continue reading... » 2 Comments
24 March 2007
VCs filling biotech funding gap
If there’s one sure rule about private equity, it is that there are no rules about private equity! Venture capitalists will tell you that they have different investment philosophies than everyone else, they’ll tell you that they’re not venture capitalists, they’ll tell you that they focus on areas that everyone else ignores.
So, it should come [...]
continue reading... » 0 Comments
22 March 2007
Angels filling biotechnology funding gap
Biotechnology companies have been facing a widening funding gap. Between frozen federal research budgets and a growing focus among venture capitalists and senior partners for larger, more mature, biotechnology firms - at the expense of smaller ones - a funding gap is growing between basic research and initial proof-of-principle commercial research.
So, who fills the gap [...]
